Brian Hoyt, MD
Dermatology · Bellingham, WANPI 1558789560
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 54.4% of the total. Reporting peaked in 2020 at $397 and has fallen 76.4% since, to $94 in 2025.
Across 83 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$860
- Regeneron Healthcare Solutions, Inc.$242
- Sun Pharmaceutical Industries Inc.$92
- Sanofi$91
- UCB, Inc.$82
- Helsinn Therapeutics (U.S.), Inc.$41
- plus $172 from 7 others
What the payments were for
- Food & beverage$1,581100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $860 |
| Regeneron Healthcare Solutions, Inc. | 8 | $242 |
| Sun Pharmaceutical Industries Inc. | 5 | $92 |
| Sanofi | 3 | $91 |
| UCB, Inc. | 4 | $82 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Galderma Laboratories, L.p. | 2 | $29 |
| Kyowa Kirin, Inc. | 2 | $27 |
| Novartis | 2 | $26 |
| DUSA Pharmaceuticals, Inc. | 2 | $24 |
| Lilly USA, LLC | 1 | $19 |
| Amgen | 1 | $14 |
How this compares
$1,581 in reported general payments places this provider in the 60th percentile of 323 dermatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 77 | $4,112 |
| Tacrolimus | 30 | $2,705 |
| Ketoconazole | 117 | $1,817 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 89 | $1,203 |
| Triamcinolone Acetonide | 98 | $1,136 |
| Fluorouracil | 18 | $1,115 |
| Clindamycin Phosphate | 34 | $895 |
| Metronidazole | 15 | $665 |
| Doxycycline Hyclate | 17 | $569 |
| ValacyclovirValacyclovir Hcl | 23 | $538 |
| Alclometasone Dipropionate | 11 | $414 |
| Minoxidil | 21 | $271 |
| Mupirocin | 35 | $243 |
| Terbinafine Hcl | 19 | $150 |
| Gabapentin | 14 | $130 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Bellingham
- Ting-Lin YangBellingham$124K
- Clive LiuBellevue$2.9M
- Vivian ShiSeattle$971K
- William WerschlerSpokane$948K
- Daniel LevyBonney Lake$541K
- Daniel SugaiBellevue$302K
- James CollyerSeattle$115K
- Cameron ChesnutSpokane$93K
- Alison YoungSeattle$53K
- Eileen SmithWalla Walla$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.